TABLE OF CONTENTS
1 INTRODUCTION 52
1.1 OBJECTIVES OF THE STUDY 52
1.2 MARKET DEFINITION 52
1.3 OVERVIEW OF THE EUROPE VENOUS DISEASES TREATMENT MARKET 52
1.4 CURRENCY AND PRICING 54
1.5 LIMITATIONS 55
1.6 MARKETS COVERED 55
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 62
2.4 DBMR TRIPOD DATA VALIDATION MODEL 63
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.6 MULTIVARIATE MODELLING 67
2.7 MARKET END USER COVERAGE GRID 68
2.8 INSTRUMENT BASED LIFELINE CURVE 69
2.9 DBMR MARKET POSITION GRID 70
2.10 VENDOR SHARE ANALYSIS 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73
3 EXECUTIVE SUMMARY 74
4 PREMIUM INSIGHTS 77
4.1 PESTEL ANALYSIS 78
4.2 PORTER'S FIVE FORCES 79
5 EUROPE VENOUS DISEASES TREATMENT MARKET, INDUSTRY INSIGHTS 80
6 EPIDEMIOLOGY 82
7 REGULATORY FRAMEWORK 83
8 MARKET OVERVIEW 86
8.1 DRIVERS 88
8.1.1 RISING INCIDENCES OF VENOUS DISEASES 88
8.1.2 RAPID CHANGES IN LIFESTYLE LEAD TO OBESITY RESULTING IN VENOUS DISEASES 88
8.1.3 INCREASE IN THE GERIATRIC POPULATION 89
8.1.4 TECHNOLOGICALLY ADVANCEMENT IN THE TREATMENT OF VENOUS DISEASES 90
8.2 RESTRAINTS 91
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 91
8.2.2 INADEQUATE REIMBURSEMENT COVERAGE 91
8.3 OPPORTUNITIES 92
8.3.1 RISING AWARENESS TOWARDS VENOUS DISORDERS 92
8.3.2 NEED FOR PROPER DIAGNOSIS AND TREATMENT OF VENOUS DISEASES 92
8.3.3 GROWING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES 93
8.3.4 OCCUPATIONAL LIFESTYLE INCREASES THE NEED FOR VENOUS DISEASE TREATMENT 93
8.4 CHALLENGES 94
8.4.1 HIGH COST ASSOCIATED WITH VENOUS DISEASE TREATMENT 94
8.4.2 SIDE EFFECTS AND RISK ASSOCIATED WITH DIFFERENT TREATMENT MODES 95
9 EUROPE VENOUS DISEASES TREATMENT MARKET, BY PRODUCT TYPE 96
9.1 OVERVIEW 97
9.2 SCLEROTHERAPY INJECTION 100
9.2.1 SCLEROTHERAPY, BY TYPE 100
9.2.1.1 INTRAVENOUS 101
9.2.1.2 INTRADERMAL 101
9.2.1.3 SUBCUTANEOUS 101
9.2.2 SUBCUTANEOUS, BY APPLICATION 101
9.2.2.1 MALFORMED LYMPHED VESSELS 101
9.2.2.2 HEMORRHOIDS 101
9.2.2.3 HYDROCELES 101
9.2.2.4 OTHERS 101
9.3 ABLATION DEVICES 101
9.3.1 THERMAL ABLATION 102
9.3.1.1 RADIOFREQUENCY 103
9.3.1.1.1 CATHETER MANIPULATION SYSTEMS 103
9.3.1.1.2 TEMPERATURE CONTROLLED 103
9.3.1.1.3 FLUID COOLED 104
9.3.1.2 LIGHT 104
9.3.1.2.1 EXCIMER LASERS 104
9.3.1.2.2 COLD LASERS 104
9.3.1.3 ULTRASOUND 104
9.3.1.3.1 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) 105
9.3.1.3.2 SHOCK WAVE LITHOTRIPSY 105
9.3.1.3.3 MAGNETIC RESONANCE IMAGING GUIDED FOCUSED ULTRASOUND (MRI-FUS) 105
9.3.1.3.4 ULTRASONIC SURGICAL SYSTEMS 105
9.3.1.4 RADIATION 105
9.3.1.4.1 STEREOTACTIC BODY RADIATION THERAPY 106
9.3.1.4.2 INTENSITY-MODULATED RADIATION THERAPY 106
9.3.1.4.3 STEREOTACTIC RADIOTHERAPY & RADIOSURGERY 106
9.3.1.4.4 IMAGE GUIDED RADIATION THERAPY 106
9.3.1.4.5 INTRAVASCULAR BRACHYTHERAPY 106
9.3.1.4.6 PROTON BEAM THERAPY 106
9.3.1.5 ELECTRICAL 106
9.3.1.5.1 ELECTRICAL ABLATORS 107
9.3.1.5.2 ELECTRONIC BRACHYTHERAPY 107
9.3.1.6 MICROWAVE 107
9.3.1.7 HYDROTHERMAL 107
9.3.2 NON-THERMAL ABLATION 107
9.3.2.1 CRYOABLATION 107
9.3.2.1.1 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES 108
9.3.2.1.2 CRYOGEN SPRAY PROBE 108
9.3.2.1.3 TISSUE CONTACT PROBE 108
9.3.2.2 HYDROMECHANICAL ABLATION 108
9.4 VENOUS CLOSURE PRODUCTS 108
9.4.1 VENOUS CLOSURE PRODUCTS, BY PROCEDURE 109
9.4.1.1 INTERVENTIONAL CARDIOLOGY 109
9.4.1.2 INTERVENTIONAL RADIOLOGY 109
9.4.2 VENOUS CLOSURE PRODUCTS, BY TECHNOLOGY 109
9.4.2.1 FEMORAL ACCESS TECHNIQUE 110
9.4.2.2 RADIAL ACCESS TECHNIQUE 110
9.5 VENOUS STENTS 110
9.5.1 VENOUS STENTS, BY TECHNOLOGY 111
9.5.1.1 WALLSTENT TECHNOLOGY 111
9.5.1.2 ILIAC VEIN STENT TECHNOLOGY 111
9.5.2 VENOUS STENTS, BY APPLICATION 111
9.5.2.1 LEG 112
9.5.2.2 CHEST 112
9.5.2.3 ABDOMEN 112
9.5.2.4 OTHERS 112
9.6 MEDICATION 112
9.7 OTHERS 113
10 EUROPE VENOUS DISEASES TREATMENT MARKET, BY DISEASE TYPE 114
10.1 OVERVIEW 115
10.2 VARICOSE VEINS 118
10.3 DEEP VEIN THROMBOSIS (DVT) 118
10.4 PULMONARY EMBOLISM 119
10.5 CHRONIC VENOUS INSUFFICIENCY (CVI) 120
10.6 SUPERFICIAL THROMBOPHLEBITIS 120
10.7 OTHERS 121
11 EUROPE VENOUS DISEASES TREATMENT MARKET, BY TREATMENT TYPE 123
11.1 OVERVIEW 124
11.2 SCLEROTHERAPY 127
11.3 RADIOFREQUENCY ABLATION THERAPY 127
11.4 LASER TREATMENT 128
11.5 AMBULATORY PHLEBECTOMY 129
11.6 VEIN LIGATION AND STRIPPING 129
11.7 ANGIOPLASTY OR STENTING 130
11.8 SURGERIES 131
11.9 COMPRESSION THERAPY 131
11.10 VEINACTIVE MEDICATION 132
11.11 VENA CAVA FILTER 133
11.12 OTHER THERAPIES 134
12 EUROPE VENOUS TREATMENT DISEASES MARKET, BY END USER 135
12.1 OVERVIEW 136
12.2 HOSPITALS 139
12.3 CLINICS 139
12.4 AMBULATORY SURGICAL CENTERS 140
12.5 OTHERS 141
13 EUROPE VENOUS DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 142
13.1 OVERVIEW 143
13.2 DIRECT TENDER 146
13.3 RETAIL SALES 146
13.4 OTHERS 147
14 EUROPE VENOUS DISEASES TREATMENT MARKET, BY REGION 148
14.1 EUROPE 149
14.1.1 GERMANY 160
14.1.2 U.K. 166
14.1.3 FRANCE 172
14.1.4 ITALY 178
14.1.5 RUSSIA 184
14.1.6 SPAIN 190
14.1.7 TURKEY 196
14.1.8 NETHERLANDS 202
14.1.9 BELGIUM 208
14.1.10 SWITZERLAND 214
14.1.11 IRELAND 220
14.1.12 REST OF EUROPE 226
15 EUROPE VENOUS DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 227
15.1 COMPANY SHARE ANALYSIS: EUROPE 227
16 SWOT ANALYSIS 228
17 COMPANY PROFILE 229
17.1 MEDTRONIC 229
17.1.1 COMPANY SNAPSHOT 229
17.1.2 REVENUE ANALYSIS 229
17.1.3 COMPANY SHARE ANALYSIS 230
17.1.4 PRODUCT PORTFOLIO 230
17.1.5 RECENT DEVELOPMENTS 230
17.2 BOSTON SCIENTIFIC CORPORATION 231
17.2.1 COMPANY SNAPSHOT 231
17.2.2 REVENUE ANALYSIS 231
17.2.3 COMPANY SHARE ANALYSIS 232
17.2.4 PRODUCT PORTFOLIO 232
17.2.5 RECENT DEVELOPMENTS 233
17.3 VARIAN MEDICAL SYSTEMS, INC. 234
17.3.1 COMPANY SNAPSHOT 234
17.3.2 COMPANY SHARE ANALYSIS 234
17.3.3 PRODUCT PORTFOLIO 235
17.3.4 RECENT DEVELOPMENT 235
17.4 STRYKER 236
17.4.1 COMPANY SNAPSHOT 236
17.4.2 REVENUE ANALYSIS 236
17.4.3 COMPANY SHARE ANALYSIS 237
17.4.4 PRODUCT PORTFOLIO 237
17.4.5 RECENT DEVELOPMENT 237
17.5 KONINKLIJKE PHILIPS N.V. 238
17.5.1 COMPANY SNAPSHOT 238
17.5.2 REVENUE ANALYSIS 238
17.5.3 COMPANY SHARE ANALYSIS 239
17.5.4 PRODUCT PORTFOLIO 239
17.5.5 RECENT DEVELOPMENT 239
17.6 ABBOTT 240
17.6.1 COMPANY SNAPSHOT 240
17.6.2 REVENUE ANALYSIS 240
17.6.3 PRODUCT PORTFOLIO 241
17.6.4 RECENT DEVELOPMENT 241
17.7 ALMA LASERS 242
17.7.1 COMPANY SNAPSHOT 242
17.7.2 PRODUCT PORTFOLIO 242
17.7.3 RECENT DEVELOPMENT 242
17.8 ANGIODYNAMICS 243
17.8.1 COMPANY SNAPSHOT 243
17.8.2 REVENUE ANALYSIS 243
17.8.3 PRODUCT PORTFOLIO 244
17.8.4 RECENT DEVELOPMENT 244
17.9 B.BRAUN MELSUNGEN AG 245
17.9.1 COMPANY SNAPSHOT 245
17.9.2 REVENUE ANALYSIS 245
17.9.3 PRODUCT PORTFOLIO 246
17.9.4 RECENT DEVELOPMENTS 246
17.10 BAYLIS MEDICAL COMPANY, INC 247
17.10.1 COMPANY SNAPSHOT 247
17.10.2 PRODUCT PORTFOLIO 247
17.10.3 RECENT DEVELOPMENT 247
17.11 BD 248
17.11.1 COMPANY SNAPSHOT 248
17.11.2 REVENUE ANALYSIS 248
17.11.3 PRODUCT PORTFOLIO 249
17.11.4 RECENT DEVELOPMENT 249
17.12 CANDELA MEDICAL 250
17.12.1 COMPANY SNAPSHOT 250
17.12.2 PRODUCT PORTFOLIO 250
17.12.3 RECENT DEVELOPMENT 250
17.13 CARL ZEISS MEDITEC AG 251
17.13.1 COMPANYSNAPSHOT 251
17.13.2 REVENUE ANALYSIS 251
17.13.3 PRODUCT PORTFOLIO 252
17.13.4 RECENT DEVELOPMENT 252
17.14 COOK 253
17.14.1 COMPANY SNAPSHOT 253
17.14.2 PRODUCT PORTFOLIO 253
17.14.3 RECENT DEVELOPMENTS 253
17.15 IMRICOR 254
17.15.1 COMPANY SNAPSHOT 254
17.15.2 REVENUE ANALYSIS 254
17.15.3 PRODUCT PORTFOLIO 255
17.15.4 RECENT DEVELOPMENT 255
17.16 OLYMPUS CORPORATION 256
17.16.1 COMPANY SNAPSHOT 256
17.16.2 REVENUE ANALYSIS 256
17.16.3 PRODUCT PORTFOILIO 257
17.16.4 RECENT DEVELOPMENT 257
17.17 OPTIMED MEDIZINISCHE INSTRUMENTE GMBH 258
17.17.1 COMPANY SNAPSHOT 258
17.17.2 PRODUCT PORTFOLIO 258
17.17.3 RECENT DEVELOPMENTS 258
17.18 PLUSMEDICA.DE 259
17.18.1 COMPANY SNAPSHOT 259
17.18.2 PRODUCT PORTFOLIO 259
17.18.3 RECENT DEVELOPMENT 259
17.19 SCITECH 260
17.19.1 COMPANY SNAPSHOT 260
17.19.2 PRODUCT PORTFOLIO 260
17.19.3 RECENT DEVELOPMENTS 260
17.20 SMITH + NEPHEW 261
17.20.1 COMPANY SNAPSHOT 261
17.20.2 REVENUE ANALYSIS 261
17.20.3 PRODUCT PORTFOLIO 262
17.20.4 RECENT DEVELOPMENT 262

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.